NZ771568A - Bispecific antibodies against plasma kallikrein and factor xii - Google Patents

Bispecific antibodies against plasma kallikrein and factor xii

Info

Publication number
NZ771568A
NZ771568A NZ771568A NZ77156815A NZ771568A NZ 771568 A NZ771568 A NZ 771568A NZ 771568 A NZ771568 A NZ 771568A NZ 77156815 A NZ77156815 A NZ 77156815A NZ 771568 A NZ771568 A NZ 771568A
Authority
NZ
New Zealand
Prior art keywords
light chain
plasma kallikrein
factor xii
bispecific antibodies
heavy chain
Prior art date
Application number
NZ771568A
Other languages
English (en)
Inventor
Jon Kenniston
Burt Adelman
Stephen Comeau
Andrew Nixon
Niksa Kastrapeli
Gregory Conley
Shauna Mason
Allison Lindberg
Kristopher Kopacz
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Priority claimed from NZ733580A external-priority patent/NZ733580B2/en
Publication of NZ771568A publication Critical patent/NZ771568A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ771568A 2015-01-02 2015-12-31 Bispecific antibodies against plasma kallikrein and factor xii NZ771568A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562099236P 2015-01-02 2015-01-02
US201562200363P 2015-08-03 2015-08-03
US201562261609P 2015-12-01 2015-12-01
NZ733580A NZ733580B2 (en) 2015-12-31 Bispecific antibodies against plasma kallikrein and factor xii

Publications (1)

Publication Number Publication Date
NZ771568A true NZ771568A (en) 2024-11-29

Family

ID=56285069

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ771568A NZ771568A (en) 2015-01-02 2015-12-31 Bispecific antibodies against plasma kallikrein and factor xii

Country Status (13)

Country Link
US (2) US11390687B2 (enExample)
EP (2) EP4670785A2 (enExample)
JP (4) JP6744313B2 (enExample)
KR (2) KR102670705B1 (enExample)
CN (2) CN107405399B (enExample)
AU (2) AU2015373910B2 (enExample)
CA (1) CA2972800A1 (enExample)
CO (1) CO2017007123A2 (enExample)
EA (1) EA201791527A1 (enExample)
IL (2) IL253180B2 (enExample)
MX (2) MX2017008541A (enExample)
NZ (1) NZ771568A (enExample)
WO (1) WO2016109774A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2972800A1 (en) 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
AU2016297018B9 (en) * 2015-07-21 2022-12-01 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor XIIa
BR112019005172A2 (pt) * 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra
CA3053010A1 (en) 2017-02-08 2018-08-16 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3054079A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
CN113004391A (zh) * 2017-08-16 2021-06-22 蜻蜓疗法股份有限公司 结合nkg2d、cd16和egfr、ccr4或pd-l1的蛋白质
EP3697815A2 (en) * 2017-10-18 2020-08-26 REGENXBIO Inc. Fully-human post-translationally modified antibody therapeutics
CN111801580B (zh) * 2018-01-12 2024-08-23 建新公司 用于定量多肽的方法
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
JP2021512914A (ja) 2018-02-08 2021-05-20 ドラゴンフライ セラピューティクス， インコーポレイテッド ナチュラルキラー細胞を活性化する多特異的結合タンパク質を伴うがんの併用療法
SG11202007945UA (en) 2018-02-20 2020-09-29 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
CA3103088A1 (en) * 2018-06-08 2019-12-12 Modalis Therapeutics Corporation Modified cas9 protein and use thereof
JP2021530989A (ja) * 2018-07-11 2021-11-18 モメンタ ファーマシューティカルズ インコーポレイテッド ＰＤ−Ｌ１を標的とした改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
US20210206859A1 (en) * 2018-08-08 2021-07-08 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
KR20250112921A (ko) * 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
CN112912099A (zh) * 2018-10-24 2021-06-04 夏尔-Nps医药品有限公司 Glp-2融合多肽和用于治疗和预防胃肠病症的用途
MX2022001049A (es) * 2019-07-26 2022-05-03 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
BR112022021884A2 (pt) 2020-05-06 2022-12-20 Dragonfly Therapeutics Inc Proteínas que se ligam a nkg2d, cd16 e clec12a
WO2022094255A2 (en) * 2020-10-29 2022-05-05 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof
CN114790246A (zh) * 2021-01-25 2022-07-26 成都康弘生物科技有限公司 一种抗体及其用途
CN114790245A (zh) * 2021-01-25 2022-07-26 成都康弘生物科技有限公司 一种抗体及其用途
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
WO2022223001A1 (zh) * 2021-04-22 2022-10-27 广东菲鹏制药股份有限公司 双特异性多功能融合多肽
WO2024238407A2 (en) * 2023-05-12 2024-11-21 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US5500349A (en) 1989-01-27 1996-03-19 Coagen Limited Blood-coagulation factor XIIA β monoclonal antibody and immunoassay
GB8901859D0 (en) 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
AU7793291A (en) 1990-05-10 1991-11-27 Cetus Corporation Inhibitors of factor xii activation and applications thereof
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5759573A (en) 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
ATE437232T1 (de) 1993-10-25 2009-08-15 Canji Inc Rekombinanter adenoviren-vektor und verfahren zur verwendung
RO116341B1 (ro) 1993-11-16 2001-01-30 Depotech Corp La Jolia Lipozom multivezicular si procedeu de obtinere a acestuia
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
GB9609262D0 (en) 1996-05-02 1996-07-03 Isis Innovation Peptide library and method
EP0953052B1 (en) 1996-05-06 2009-03-04 Oxford BioMedica (UK) Limited Crossless retroviral vectors
EP1158997A2 (en) 1999-03-09 2001-12-05 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
CN101260156A (zh) * 2002-06-28 2008-09-10 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
BRPI0519349A8 (pt) 2004-12-23 2017-09-12 Csl Behring Gmbh Prevenção de formação e/ou estabilização de trombos
GB0500487D0 (en) 2005-01-11 2005-02-16 Axis Shield Diagnostics Ltd Forms of factor XIIa
US7932021B2 (en) 2005-07-28 2011-04-26 American Diagnostica, Inc. Lupus anticoagulant testing
GB0607515D0 (en) 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
SI2373691T1 (sl) 2008-12-18 2019-05-31 Oregon Health & Science University Protitelesa proti FXI in postopki uporabe
AU2011204349C1 (en) 2010-01-06 2017-02-16 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
HRP20180421T1 (hr) 2010-11-17 2018-04-20 Chugai Seiyaku Kabushiki Kaisha Višestruko specifične molekule za vezanje na antigen koje imaju alternativnu funkciju u odnosu na funkciju faktora viii zgrušavanja krvi
WO2012094587A1 (en) * 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
EP2548892A1 (en) 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
EP4516811A3 (en) * 2011-07-22 2025-03-26 CSL Behring GmbH Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
JP5653860B2 (ja) 2011-07-28 2015-01-14 富士フイルム株式会社 管壁の硬度測定方法および装置
EP2765192A4 (en) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd ANTIGEN BINDING MOLECULE FOR PROMOTING THE PLASMA CLAIR OF AN ANTIGEN COMPRISING A SACCHARIDIC CHAIN TYPE RECEPTOR BINDING DOMAIN
HRP20201004T1 (hr) 2011-12-20 2020-10-16 Medimmune, Llc Modificirani polipeptidi za skelete bispecifičnog protutijela
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
JP6348900B2 (ja) 2012-05-10 2018-06-27 バイエル ファーマ アクチエンゲゼルシャフト 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途
US20140038204A1 (en) 2012-07-31 2014-02-06 Baxter Healthcare S.A. Selective measurement of active human protease coagulation factors
WO2014089493A1 (en) 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
SMT201900204T1 (it) * 2013-01-20 2019-05-10 Dyax Corp Valutazione, saggi e trattamento di disturbi mediati da pkal
KR20150132473A (ko) 2013-03-15 2015-11-25 다이액스 코포레이션 항-혈장 칼리크레인 항체
WO2014207199A1 (en) * 2013-06-28 2014-12-31 Csl Behring Gmbh Combination therapy using a factor xii inhibitor and a c1-inhibitor
EP4067383A1 (en) 2013-07-25 2022-10-05 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
CA2972800A1 (en) 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
AU2016297018B9 (en) 2015-07-21 2022-12-01 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor XIIa
EP3263803B1 (en) 2016-06-30 2019-08-14 ABB Schweiz AG Substation

Also Published As

Publication number Publication date
EA201791527A1 (ru) 2017-12-29
BR112017014308A2 (pt) 2018-03-06
CN114316061A (zh) 2022-04-12
US12240918B2 (en) 2025-03-04
WO2016109774A1 (en) 2016-07-07
KR20170118058A (ko) 2017-10-24
CN107405399B (zh) 2022-02-08
MX2017008541A (es) 2017-12-04
JP2020186248A (ja) 2020-11-19
JP7003347B2 (ja) 2022-02-04
AU2022201076A1 (en) 2022-03-10
EP3240570A4 (en) 2018-08-08
JP2023065659A (ja) 2023-05-12
CN107405399A (zh) 2017-11-28
JP2018502572A (ja) 2018-02-01
EP3240570B1 (en) 2025-09-24
US20180118851A1 (en) 2018-05-03
NZ733580A (en) 2024-02-23
EP4670785A2 (en) 2025-12-31
AU2015373910A1 (en) 2017-07-27
KR20240091031A (ko) 2024-06-21
JP2022023038A (ja) 2022-02-07
EP3240570A1 (en) 2017-11-08
IL298086A (en) 2023-01-01
JP7241827B2 (ja) 2023-03-17
IL298086B1 (en) 2024-07-01
US11390687B2 (en) 2022-07-19
MX2024000317A (es) 2024-01-25
KR102670705B1 (ko) 2024-05-31
EP3240570C0 (en) 2025-09-24
CA2972800A1 (en) 2016-07-07
JP6744313B2 (ja) 2020-08-26
IL298086B2 (en) 2024-11-01
JP7635285B2 (ja) 2025-02-25
AU2022201076B2 (en) 2025-05-15
AU2015373910B2 (en) 2021-11-18
CO2017007123A2 (es) 2017-12-15
US20230117565A1 (en) 2023-04-20
CN114316061B (zh) 2024-11-01
IL253180B2 (en) 2023-04-01
IL253180A0 (en) 2017-08-31
IL253180B (en) 2022-12-01

Similar Documents

Publication Publication Date Title
MX2024000317A (es) Anticuerpos biespecificos contra calicreina y factor xii del plasma.
EA201990285A1 (ru) Гетеродимерные иммуноглобулиновые конструкции и способы их получения
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
GEAP202215170A (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
PH12018500635A1 (en) Bispecific antibodies specific for pd1 and tim3
CR20190435A (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3
EA201990894A9 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
MX2015008623A (es) Anticuerpos que se unen al ligando 1a tipo tnf y sus usos.
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
MX2023006511A (es) Un anticuerpo monoclonal inhibidor del factor xiia.
ZA202208337B (en) A bispecific anti-pd-l1/vegf antibody and uses thereof
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
MX2019011585A (es) Anticuerpos miltiespecificos estables.
ZA202205288B (en) Humanized antibody and method for using the same
EA201990253A1 (ru) Гуманизированные антитела против s100a9 и их применение
MX2019005552A (es) Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.
IL280745A (en) Anti-FC epsilon-R1 alpha (FCER1A) antibodies, bispecific antigen-binding molecules that bind FCER1A and CD3, and uses thereof
BR112018076247A2 (pt) anticorpos monoclonais quiméricos e humanizados para cd81
ZA202106551B (en) Anti-bag2 antibody and methods of treating cancer
AR101185A1 (es) Anticuerpos anti-factor v o factor v activado
EA202091053A1 (ru) Модифицированные c- и ch1-домены

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20210702

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 DEC 2026 BY ANAQUA SERVICES

Effective date: 20251120